Medicare seeks comments for Alzheimer’s treatment national coverage policy
The Centers for Medicare & Medicaid Services is accepting comments through Aug. 11 on whether to establish a national Medicare coverage policy for monoclonal antibodies to treat Alzheimer’s disease.
The Food and Drug Administration recently approved the first such drug (aducanumab) through an accelerated pathway that requires the company to verify clinical benefit in a post-approval trial. Medicare administrative contractors are currently making coverage determinations for aducanumab at the local level.
Stakeholders may register for CMS webinars July 22 to learn more or comment. CMS plans to release a proposed decision within six months and a final decision within nine months.
Related News Articles
Headline
An analysis by KFF released last week found that in 2022, Medicare spent 27% ($2,585) more, on average, for individuals covered by Traditional Medicare after…
Headline
A House Dear Colleague letter calling on House leadership to address scheduled Medicaid Disproportionate Share Hospital payment cuts received signatures from…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…
Headline
In comments Dec. 9 to the Medicare Payment Advisory Commission, the AHA shared its views on physician fee schedule payments, advanced alternative payment model…
Headline
The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to the Medicare Advantage and prescription drug programs for contract year 2026.…
Headline
The AHA commented Nov. 26 on the Centers for Medicare & Medicaid Services’ hospital inpatient prospective payment system interim final action on revising…